News >

Expert Highlights Ongoing Advances in Multiple Myeloma

Brandon Scalea
Published: Thursday, Feb 07, 2019

Sarah Holstein, MD, PhD

Sarah Holstein, MD, PhD

There is a plethora of treatment options for patients with relapsed/refractory myeloma, but the challenge for physicians lies in defining an optimal treatment sequence, particularly when a patient becomes refractory to lenalidomide (Revlimid), said Sarah Holstein, MD, PhD.

In heavily pretreated patients, CAR T-cell therapy has emerged as a method to generate deep responses. At the 2018 ASH Annual Meeting, data from the next-generation CAR T product, bb21217, showed encouraging efficacy and promising safety. In the phase I CRB-402 trial, data showed an objective response rate of 83.3%, with a very good partial response or better rate of 75%.1 Additionally, complete remissions were observed out to 10 months after infusion.

bb21217 follows bb2121, which garnered attention at the 2018 ASCO Annual Meeting due to its impressive progression-free survival (PFS) and response rates in a penta-refractory patient population.2

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x